Literature DB >> 2746199

Elevated plasma prostaglandin E2 levels in schizophrenia.

H Kaiya1, M Uematsu, M Ofuji, A Nishida, K Takeuchi, M Nozaki, E Idaka.   

Abstract

Plasma levels of prostaglandin E2 (PGE2) were determined with radioimmunoassay in 40 DSM-III schizophrenics, 15 patients with other mental disorders, and 23 normal controls. The mean value of plasma immunoreactivity of PGE2 was significantly higher in the schizophrenic patients than in the normal controls. Schizophrenic patients with high plasma PGE2 levels had more guilt feelings and hallucinatory behavior on BPRS, relatively successful heterosexual relations, and a higher incidence of birth complications.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2746199     DOI: 10.1007/bf01255817

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  25 in total

1.  Determination of prostaglandin E2 in plasma of schizophrenics and healthy controls by gas chromatography-negative-ion chemical ionization mass spectrometry and radioimmunoassay.

Authors:  E Idaka; H Kaiya; H Horitsu
Journal:  J Chromatogr       Date:  1987-09-25

2.  The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia.

Authors:  J S Strauss; W T Carpenter
Journal:  Arch Gen Psychiatry       Date:  1974-07

3.  The influence of psychotropic drugs on prostaglandin biosynthesis.

Authors:  R E Lee
Journal:  Prostaglandins       Date:  1974-01-10

4.  Metabolic products of arachidonic acid in the central nervous system: possible role in mental disorders.

Authors:  A A Mathé; B Apéria; P Bergman; G Eberhard; M Jerling; L Lindström; J Sääf; F Undén; L Wetterberg
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1987

5.  Cerebrospinal fluid prostaglandin E in depression, mania, and schizophrenia compared to normals.

Authors:  R H Gerner; J E Merrill
Journal:  Biol Psychiatry       Date:  1983-05       Impact factor: 13.382

6.  Alpha-adrenergic receptors and cyclic AMP production in a group of schizophrenic patients.

Authors:  M S Kafka; J E Kleinman; C N Karson; R J Wyatt
Journal:  Hillside J Clin Psychiatry       Date:  1986

7.  Effect of ADP on PGE1 formation in blood platelets from patients with depression, mania and schizophrenia.

Authors:  Y H Abdulla; K Hamadah
Journal:  Br J Psychiatry       Date:  1975-12       Impact factor: 9.319

8.  The effect of phenothiazines and their metabolites on prostaglandin production by rat basophilic leukemia cells in culture.

Authors:  V A Rigas; H Van Vunakis; L Levine
Journal:  Prostaglandins Med       Date:  1981-08

9.  alpha-Adrenergic receptor function in schizophrenia. Receptor number, cyclic adenosine monophosphate production, adenylate cyclase activity, and effect of drugs.

Authors:  M S Kafka; D P van Kammen
Journal:  Arch Gen Psychiatry       Date:  1983-03

10.  Schizophrenia as a prostaglandin deficiency disease.

Authors:  D F Horrobin
Journal:  Lancet       Date:  1977-04-30       Impact factor: 79.321

View more
  13 in total

Review 1.  [Immunology in schizophrenic disorders].

Authors:  N Müller; M J Schwarz
Journal:  Nervenarzt       Date:  2007-03       Impact factor: 1.214

Review 2.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Authors:  N Muller; M Schwarz
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

3.  Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia.

Authors:  Bin Tang; Cristina Capitao; Brian Dean; Elizabeth A Thomas
Journal:  Psychiatry Res       Date:  2012-03-06       Impact factor: 3.222

Review 4.  Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.

Authors:  Joana Prata; Susana G Santos; Maria Inês Almeida; Rui Coelho; Mário A Barbosa
Journal:  J Neuroinflammation       Date:  2017-09-04       Impact factor: 8.322

5.  Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA.

Authors:  Miran Kenk; Thiviya Selvanathan; Naren Rao; Ivonne Suridjan; Pablo Rusjan; Gary Remington; Jeffrey H Meyer; Alan A Wilson; Sylvain Houle; Romina Mizrahi
Journal:  Schizophr Bull       Date:  2014-11-09       Impact factor: 9.306

6.  Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia.

Authors:  Borja García-Bueno; Miquel Bioque; Karina S Mac-Dowell; M Fe Barcones; Monica Martínez-Cengotitabengoa; Laura Pina-Camacho; Roberto Rodríguez-Jiménez; Pilar A Sáiz; Carmen Castro; Amalia Lafuente; Javier Santabárbara; Ana González-Pinto; Mara Parellada; Gabriel Rubio; M Paz García-Portilla; Juan A Micó; Miguel Bernardo; Juan C Leza
Journal:  Schizophr Bull       Date:  2013-03-13       Impact factor: 9.306

Review 7.  Metabolomics Biomarkers for Precision Psychiatry.

Authors:  Pei-An Betty Shih
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 8.  Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.

Authors:  Tatsurou Yagami; Hiromi Koma; Yasuhiro Yamamoto
Journal:  Mol Neurobiol       Date:  2015-09-02       Impact factor: 5.590

Review 9.  A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders.

Authors:  Norbert Müller; Markus J Schwarz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06       Impact factor: 5.270

10.  Molecular profiles of parvalbumin-immunoreactive neurons in the superior temporal cortex in schizophrenia.

Authors:  Charmaine Y Pietersen; Sarah A Mauney; Susie S Kim; Eleonora Passeri; Maribel P Lim; Robert J Rooney; Jill M Goldstein; Tracey L Petreyshen; Larry J Seidman; Martha E Shenton; Robert W Mccarley; Kai-C Sonntag; Tsung-Ung W Woo
Journal:  J Neurogenet       Date:  2014-03-17       Impact factor: 1.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.